Asceneuron is a startup based in Switzerland, most recent round Series-c-plus, 1 tracked investor.
Asceneuron is a startup founded in 2015 based in Switzerland. Its most recent tracked round is Series-c-plus. Brouky records 1 investor associated with the company.
Asceneuron is a clinical-stage biotechnology company developing novel orally available therapeutics for neurodegenerative diseases. Their lead compound, ASN90, is an O-GlcNAcase inhibitor currently in clinical development for Multiple System Atrophy.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.